{"id":687,"date":"2025-12-31T10:05:10","date_gmt":"2025-12-31T10:05:10","guid":{"rendered":"https:\/\/grandforecast.com\/index.php\/2025\/12\/31\/top-4-canadian-biotech-stocks-of-2025\/"},"modified":"2025-12-31T10:05:10","modified_gmt":"2025-12-31T10:05:10","slug":"top-4-canadian-biotech-stocks-of-2025","status":"publish","type":"post","link":"https:\/\/grandforecast.com\/index.php\/2025\/12\/31\/top-4-canadian-biotech-stocks-of-2025\/","title":{"rendered":"Top 4 Canadian Biotech Stocks of 2025"},"content":{"rendered":"<\/p>\n

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.<\/strong><\/p>\n

Read on to learn what’s been driving these Canadian biotech firms.<\/p>\n

\n
<\/div>\n<\/div>\n
\n

1. Eupraxia Pharmaceuticals (TSX:EPRX)<\/h3>\n

Year-on-year gain:<\/strong> 136.75 percent
Market cap:<\/strong> C$507.5 million
Share price:<\/strong> C$10.63<\/p>\n

Eupraxia Pharmaceuticals is developing clinical candidates that employ its DiffuSphere technology, which delivers treatments to the targeted tissues. <\/p>\n

The company’s candidates are currently EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis, and it is exploring the use of its technology for other active compounds as well. <\/p>\n

The company has continued to advance the treatment through clinical trials in 2025 and released multiple rounds of positive data from its Phase 1b\/2a trial cohorts.<\/p>\n

In July, Eupraxia dosed its first patient after advancing its investigation to Phase 2b trials based on safety and efficacy data from the earlier Phase 2a patient cohorts. Top-line results from the Phase 2b study are anticipated in Q3 2026.<\/p>\n

In September, the company shared data from the highest-dose cohort of the still ongoing Phase 1b\/2a trials, reporting that the group saw the largest improvements so far. Backed by a US$80.5 million public offering completed in September, Eupraxia ends 2025 capitalized through Q1 2028, the company stated. <\/p>\n<\/div>\n

\n

2. NervGen (TSXV:NGEN)<\/h3>\n

Year-on-year gain:<\/strong> 123.08 percent
Market cap:<\/strong> C$562.67 million
Share price:<\/strong> C$6.96<\/p>\n

NervGen is a clinical-stage Canadian biotechnology company that focuses on developing innovative treatments to enable the nervous system to repair itself following damage from injury or disease.<\/p>\n

The company’s core technology targets a mechanism that hinders nervous system repair. When the nervous system is damaged, chondroitin sulfate proteoglycans (CSPG) form a \u201cscar.\u201d Initially, CSPGs help contain damage, but their long-term interaction with the PTP\u03c3 receptor inhibits repair.<\/p>\n

NervGen\u2019s lead drug candidate, NVG-291, is designed to relieve these inhibitory effects to promote nervous system repair. It received fast-track designation from the US FDA. <\/p>\n

On November 24, 2025, the company announced expanded data from its Phase 1b\/2a clinical trial testing NVG-291 in patients with chronic spinal cord injury. The results showed ‘unprecedented durable’ improvements in patients, with functional gains continuing to strengthen after the 12 week treatment period ended. <\/p>\n

Compared to placebo, more patients who received the treatment reported substantially improved bladder control and muscle spasticity, and GRASSP quantitative prehension scores demonstrating a 3.7-fold greater mean improvement in hand function.<\/p>\n

NVG-300, a newer preclinical candidate, is being evaluated for ischemic stroke and SCI. <\/p>\n<\/div>\n

\n

3. Bright Minds Biosciences (CSE:DRUG)<\/h3>\n

<\/span>Year-on-year gain:<\/strong> 103.83 percent
Market cap:<\/strong> C$918.89 million
Share price:<\/strong> C$110.72<\/p>\n

Bright Minds Biosciences is developing novel serotonin agonists targeting neurocircuit abnormalities linked to neuropsychiatric disorders and epilepsy, designing next-generation treatments that aim to retain the therapeutic benefits of psychedelics while minimizing side effects. <\/p>\n

Its lead candidate, BMB-101, a selective 5-HT2C receptor agonist, has shown encouraging preclinical efficacy by stopping seizures in an epilepsy mouse model, evaluated jointly with Firefly Neuroscience (NASDAQ:AIFF). <\/p>\n

The company\u2019s stock surged nearly 1,500 percent in October 2024 following H. Lundbeck\u2019s acquisition announcement of a competitor focused on similar targets. Strengthening its epilepsy expertise, Bright Minds expanded its scientific advisory board in early 2025 by adding five leaders in the field.<\/p>\n

In 2025, Bright Minds launched the BREAKTHROUGH study, an open-label Phase 2 trial evaluating BMB-101 in adults with absence epilepsy or developmental and epileptic encephalopathy. <\/p>\n

Clinical updates presented at the American Epilepsy Society Annual Meeting on December 7 highlighted BMB-101\u2019s unique G-protein biased agonism, which aims to provide anti-seizure efficacy without the cardiovascular risks typical of older serotonin drugs. The same month, Bright Minds company expanded its scope by initiating a new Phase 2a program investigating BMB-101 for Prader-Willi Syndrome. <\/p>\n<\/div>\n

\n

4. Hemostemix (TSXV:HEM)<\/h3>\n

<\/span>Year-on-year gain:<\/strong> 21.43 percent
Market cap:<\/strong> C$16.02 million
Share price:<\/strong> C$0.09<\/p>\n

Hemostemix is a clinical-stage biotech company focused on developing autologous stem cell therapies, meaning the treatments use a patient’s own cells to theoretically enhance safety and efficacy. <\/p>\n

Its main product, ACP-01, is an autologous cell therapy designed to promote tissue repair and regeneration in areas affected by diseases, including a range of heart diseases. <\/p>\n

The company announced its first advanced sales orders for ACP-01 in Q1 2025 and has been working to expand internationally and attract new investment.<\/p>\n

Hemostemix secured the regulatory green light for commercial sales in Florida after the state passed Senate Bill 1768. The bill creates a framework in which healthcare providers can administer stem cell therapies that had not yet been approved by the US Food and Drug Administration (FDA) but meet the bill’s guidelines.<\/p>\n

The company now offers commercial ACP-01 treatments for ischemic pain in the state under the name VesCell, with sales forecasted to reach C$22.5 million in 2026. Operational plans target cash flow positivity by Q4 2026, supported by a growing physician network and commercial pipeline.<\/p>\n

Additionally, Hemostemix is currently collaborating with Firefly Neuroscience on a Phase 1 clinical trial of ACP-01 for vascular dementia. <\/p>\n

A pre-IND meeting, aiming to finalize a single Phase 1 clinical trial designed to study ACP-01 across multiple conditions simultaneously, is scheduled for January 16, 2026. <\/span><\/p>\n<\/div>\n

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.<\/strong><\/p>\n<\/p>\n

This post appeared first on investingnews.com<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies. Read on to learn what’s been driving these Canadian biotech firms. 1. Eupraxia Pharmaceuticals (TSX:EPRX) Year-on-year gain: 136.75 percentMarket cap: C$507.5 millionShare price: C$10.63 Eupraxia Pharmaceuticals […]<\/p>\n","protected":false},"author":1,"featured_media":688,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-687","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing"],"_links":{"self":[{"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/posts\/687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/comments?post=687"}],"version-history":[{"count":0,"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/posts\/687\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/media\/688"}],"wp:attachment":[{"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/media?parent=687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/categories?post=687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grandforecast.com\/index.php\/wp-json\/wp\/v2\/tags?post=687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}